New Articles -- EvidenceUpdates: Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

1. abstract + comment

   Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab.

 2. NEJM - abstract
(Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743; SOLO 2 ClinicalTrials.gov number, NCT02277769.)